|
1
|
Veldkamp R, Gholghesaei M, Bonjer HJ,
Meijer DW, Buunen M, Jeekel J, Anderberg B, Cuesta MA, Cuschierl A,
Fingerhut A, et al: European Association of Endoscopic Surgery
(EAES): Laparoscopic resection of colon Cancer: Consensus of the
European Association of Endoscopic Surgery (EAES). Surg Endosc.
18:1163–1185. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsujimoto H, Tsukioka S, Ono S, Sakamoto
E, Sakamoto K, Tsuta K, Nakagawa F, Saito H, Uchida J, Kiniwa M, et
al: Effect of leucovorin on the antitumor efficacy of the 5-FU
prodrug, tegafur-uracil, in human colorectal cancer xenografts with
various expression levels of thymidylate synthase. Oncol Lett.
1:973–980. 2010.PubMed/NCBI
|
|
3
|
Yang SY, Miah A, Sales KM, Fuller B,
Seifalian AM and Winslet M: Inhibition of the p38 MAPK pathway
sensitises human colon cancer cells to 5-fluorouracil treatment.
Int J Oncol. 38:1695–1702. 2011.PubMed/NCBI
|
|
4
|
Mechoulam R, Ben-Shabat S, Hanus L,
Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR,
Compton DR, et al: Identification of an endogenous
2-mono-glyceride, present in canine gut, that binds to cannabinoid
receptors. Biochem Pharmacol. 50:83–90. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Devane WA, Breuer A, Sheskin T, Järbe TU,
Eisen MS and Mechoulam R: A novel probe for the cannabinoid
receptor. J Med Chem. 35:2065–2069. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Di Carlo G and Izzo AA: Cannabinoids for
gastrointestinal diseases: Potential therapeutic applications.
Expert Opin Investig Drugs. 12:39–49. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
De Petrocellis L, Cascio MG and Di Marzo
V: The endocannabinoid system: A general view and latest additions.
Br J Pharmacol. 141:765–774. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Piomelli D: The molecular logic of
endocannabinoid signalling. Nat Rev Neurosci. 4:873–884. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cravatt BF, Giang DK, Mayfield SP, Boger
DL, Lerner RA and Gilula NB: Molecular characterization of an
enzyme that degrades neuromodulatory fatty-acid amides. Nature.
384:83–87. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pertwee RG: Cannabinoid Receptors.
Academic Press; New York, NY: 1995
|
|
11
|
Pertwee RG: Pharmacology of cannabinoid
CB1 and CB2 receptors. Pharmacol Ther. 74:129–180. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Di Marzo V, Melck D, De Petrocellis L and
Bisogno T: Cannabimimetic fatty acid derivatives in cancer and
inflammation. Prostaglandins Other Lipid Mediat. 61:43–61. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gonsiorek W, Lunn C, Fan X, Narula S,
Lundell D and Hipkin RW: Endocannabinoid 2-arachidonyl glycerol is
a full agonist through human type 2 cannabinoid receptor:
Antagonism by anandamide. Mol Pharmacol. 57:1045–1050.
2000.PubMed/NCBI
|
|
14
|
Guzmán M: Cannabinoids: Potential
anticancer agents. Nat Rev Cancer. 3:745–755. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ligresti A, Bisogno T, Matias I, De
Petrocellis L, Cascio MG, Cosenza V, D’argenio G, Scaglione G,
Bifulco M, Sorrentini I, et al: Possible endocannabinoid control of
colorectal cancer growth. Gastroenterology. 125:677–687. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sarnataro D, Grimaldi C, Pisanti S,
Gazzerro P, Laezza C, Zurzolo C and Bifulco M: Plasma membrane and
lysosomal localization of CB1 cannabinoid receptor are dependent on
lipid rafts and regulated by anandamide in human breast cancer
cells. FEBS Lett. 579:6343–6349. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
De Petrocellis L, Melck D, Palmisano A,
Bisogno T, Laezza C, Bifulco M and Di Marzo V: The endogenous
cannabinoid anandamide inhibits human breast cancer cell
proliferation. Proc Natl Acad Sci USA. 95:8375–8380. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Contassot E, Wilmotte R, Tenan M, Belkouch
MC, Schnüriger V, de Tribolet N, Burkhardt K and Dietrich PY:
Arachidonylethanolamide induces apoptosis of human glioma cells
through vanilloid receptor-1. J Neuropathol Exp Neurol. 63:956–963.
2004.PubMed/NCBI
|
|
19
|
Galve-Roperh I, Sánchez C, Cortés ML,
Gómez del Pulgar T, Izquierdo M and Guzmán M: Anti-tumoral action
of cannabinoids: Involvement of sustained ceramide accumulation and
extracellular signal-regulated kinase activation. Nat Med.
6:313–319. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Morad SA and Cabot MC:
Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer.
13:51–65. 2013. View
Article : Google Scholar
|
|
21
|
Grösch S, Schiffmann S and Geisslinger G:
Chain length-specific properties of ceramides. Prog Lipid Res.
51:50–62. 2012. View Article : Google Scholar
|
|
22
|
Selzner M, Bielawska A, Morse MA, Rüdiger
HA, Sindram D, Hannun YA and Clavien PA: Induction of apoptotic
cell death and prevention of tumor growth by ceramide analogues in
metastatic human colon cancer. Cancer Res. 61:1233–1240.
2001.PubMed/NCBI
|
|
23
|
Garzotto M, White-Jones M, Jiang Y,
Ehleiter D, Liao WC, Haimovitz-Friedman A, Fuks Z and Kolesnick R:
12-O-tetradecanoylphorbol-13-acetate-induced apoptosis in LNCaP
cells is mediated through ceramide synthase. Cancer Res.
58:2260–2264. 1998.PubMed/NCBI
|
|
24
|
Chmura SJ, Nodzenski E, Beckett MA, Kufe
DW, Quintans J and Weichselbaum RR: Loss of ceramide production
confers resistance to radiation-induced apoptosis. Cancer Res.
57:1270–1275. 1997.PubMed/NCBI
|
|
25
|
Verheij M, van Blitterswijk WJ and
Bartelink H: Radiation-induced apoptosis - the ceramide-SAPK
signaling pathway and clinical aspects. Acta Oncol. 37:575–581.
1998. View Article : Google Scholar
|
|
26
|
Chen L, Xie B, Li L, Jiang W, Zhang Y, Fu
J, Guan G and Qiu Y: Rapid and sensitive LC-MS/MS analysis of fatty
acids in clinical amples. Chromatographia. 77:1241–1247. 2014.
View Article : Google Scholar
|
|
27
|
Wu X, Han L, Zhang X, Li L, Jiang C, Qiu
Y, Huang R, Xie B, Lin Z, Ren J, et al: Alteration of
endocannabinoid system in human gliomas. J Neurochem. 120:842–849.
2012. View Article : Google Scholar
|
|
28
|
D’Argenio G, Valenti M, Scaglione G,
Cosenza V, Sorrentini I and Di Marzo V: Upregulation of anandamide
levels as an endogenous mechanism and a pharmacological strategy to
limit colon inflammation. FASEB J. 20:568–570. 2006.
|
|
29
|
Izzo AA, Aviello G, Petrosino S, Orlando
P, Marsicano G, Lutz B, Borrelli F, Capasso R, Nigam S, Capasso F,
et al: Endocannabinoid Research Group: Increased endocannabinoid
levels reduce the development of precancerous lesions in the mouse
colon. J Mol Med Berl. 86:89–98. 2008. View Article : Google Scholar
|
|
30
|
Melck D, De Petrocellis L, Orlando P,
Bisogno T, Laezza C, Bifulco M and Di Marzo V: Suppression of nerve
growth factor Trk receptors and prolactin receptors by
endocannabinoids leads to inhibition of human breast and prostate
cancer cell proliferation. Endocrinology. 141:118–126. 2000.
|
|
31
|
Cianchi F, Papucci L, Schiavone N, Lulli
M, Magnelli L, Vinci MC, Messerini L, Manera C, Ronconi E,
Romagnani P, et al: Cannabinoid receptor activation induces
apoptosis through tumor necrosis factor α-mediated ceramide de novo
synthesis in colon cancer cells. Clin Cancer Res. 14:7691–7700.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sánchez C, Galve-Roperh I, Rueda D and
Guzmán M: Involvement of sphingomyelin hydrolysis and the
mitogen-activated protein kinase cascade in the
Δ9-tetrahydrocannabinol-induced stimulation of glucose
metabolism in primary astrocytes. Mol Pharmacol. 54:834–843.
1998.
|
|
33
|
Ogretmen B and Hannun YA: Biologically
active sphingolipids in cancer pathogenesis and treatment. Nat Rev
Cancer. 4:604–616. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Koybasi S, Senkal CE, Sundararaj K,
Spassieva S, Bielawski J, Osta W, Day TA, Jiang JC, Jazwinski SM,
Hannun YA, et al: Defects in cell growth regulation by
C18:0-ceramide and longevity assurance gene 1 in human head and
neck squamous cell carcinomas. J Biol Chem. 279:44311–44319. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Seumois G, Fillet M, Gillet L, Faccinetto
C, Desmet C, François C, Dewals B, Oury C, Vanderplasschen A,
Lekeux P, et al: De novo C16- and C24-ceramide generation
contributes to spontaneous neutrophil apoptosis. J Leukoc Biol.
81:1477–1486. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
White-Gilbertson S, Mullen T, Senkal C, Lu
P, Ogretmen B, Obeid L and Voelkel-Johnson C: Ceramide synthase 6
modulates TRAIL sensitivity and nuclear translocation of active
caspase-3 in colon cancer cells. Oncogene. 28:1132–1141. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Osawa Y, Uchinami H, Bielawski J, Schwabe
RF, Hannun YA and Brenner DA: Roles for C16-ceramide and
sphingosine 1-phosphate in regulating hepatocyte apoptosis in
response to tumor necrosis factor-alpha. J Biol Chem.
280:27879–27887. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Senkal CE, Ponnusamy S, Bielawski J,
Hannun YA and Ogretmen B: Antiapoptotic roles of
ceramide-synthase-6-generated C16-ceramide via selective regulation
of the ATF6/CHOP arm of ER-stress-response pathways. FASEB J.
24:296–308. 2010. View Article : Google Scholar :
|
|
39
|
Cairns RA, Harris IS and Mak TW:
Regulation of cancer cell metabolism. Nat Rev Cancer. 11:85–95.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rysman E, Brusselmans K, Scheys K,
Timmermans L, Derua R, Munck S, Van Veldhoven PP, Waltregny D,
Daniëls VW, Machiels J, et al: De novo lipogenesis protects cancer
cells from free radicals and chemotherapeutics by promoting
membrane lipid saturation. Cancer Res. 70:8117–8126. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nashed M, Chisholm JW and Igal RA:
Stearoyl-CoA desaturase activity modulates the activation of
epidermal growth factor receptor in human lung cancer cells. Exp
Biol Med. 237:1007–1017. 2012. View Article : Google Scholar
|
